Biotech · Private company
Zai Lab (Shanghai) Co., Ltd.
Track this companyFree. Adds Zai Lab (Shanghai) Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials96 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- Investigator's Choice of TherapyPhase 3 · Small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- ZL-1310Phase 3 · Small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- ZL-1310Phase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 1 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
- ZL-1201Phase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- ZL-1310Phase 1 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
- ZL-6201Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected TumorsPHASE1 · RECRUITING · started Mar 2, 2026ClinicalTrials.gov NCT07374848 · fetched Nov 12, 2026
- A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)PHASE3 · RECRUITING · started Nov 30, 2025ClinicalTrials.gov NCT07218146 · fetched Nov 12, 2026
- A Study of ZL-1310 in Participants With Selected Solid TumorsPHASE1_PHASE2 · RECRUITING · started May 12, 2025ClinicalTrials.gov NCT06885281 · fetched Nov 12, 2026
- A Study of ZL-1310 in Subjects With Small Cell Lung CancerPHASE1 · RECRUITING · started Jan 23, 2024ClinicalTrials.gov NCT06179069 · fetched Nov 12, 2026
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 21, 2023ClinicalTrials.gov NCT06140836 · fetched Nov 12, 2026
- A Trial of ZL-1201 in Subjects With Advanced CancerPHASE1 · COMPLETED · started May 11, 2020ClinicalTrials.gov NCT04257617 · fetched Nov 12, 2026
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerPHASE2_PHASE3 · COMPLETED · started Sep 30, 2019ClinicalTrials.gov NCT04082364 · fetched Nov 12, 2026
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerPHASE2 · COMPLETED · started Sep 14, 2018ClinicalTrials.gov NCT03694522 · fetched Nov 12, 2026
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPHASE1_PHASE2 · RECRUITING · started Mar 7, 2017ClinicalTrials.gov NCT03093116 · fetched Nov 12, 2026